MehdiMMoeziMDFACP

Oncology • Fleming Island, FL

Breast Cancer, Gastrointestinal Cancer, Hematologic Oncology, Thoracic Cancer

Cancer Specialists of North Florida

Join to view full profile

Dr. Moezi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Moezi's full profile

Already have an account?

Office
2370 Market Dr
Fleming Island, FL 32003
Phone+1 904-363-2113

Fax+1 904-264-6858

Education & Training

SUNY Downstate Health Sciences UniversityFellowship, Hematology and Medical Oncology, 1998 - 2001
One Brooklyn Health System/Interfaith Medical CenterResidency, Internal Medicine, 1995 - 1998
Tehran University of Medical Sciences School of MedicineClass of 1990

Certifications & Licensure

CA State Medical License 2005 - Present
FL State Medical License 2000 - 2026
UT State Medical License 1998 - 2006
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013

Clinical Trials

Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts Start of enrollment: 2010 Nov 01
Completed
Phase 3
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20
Completed
Phase 3
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma Start of enrollment: 2011 Aug 04
Completed
Phase 3
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma Start of enrollment: 2011 Nov 30
Completed
Phase 2
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial.
Debu Tripathy, Joanne L Blum, Meghan S Karuturi, Steven McCune, Sobha Kurian
The Oncologist. 2024-10-30
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.
James R Berenson, Andrea Limon, Stephanie Rice, Tahmineh Safaie, Ralph Boccia
Targeted Oncology. 2024-05-01
5 citations
Fostamatinib or Thrombopoietin for the Treatment of Chronic Immune Thrombocytopenia in Adult Patients: A Real-World Assessment of Safety, Effectiveness and Cost.
George Dranitsaris, Aaron Peevyhouse, Tiffany Wood, Yuliya Kreychman, Heather Neuhalfen
Acta Haematologica. 2024-01-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member
American College of Physicians - ACP
Member
American Medical Association - AMA
Member
European Society of Medical Oncology
Member

Other Languages

Farsi